As part of its Inventive Step series, MedNous published an article by HaemaLogiX co-founder Rosanne Dunn in its March issue. 

The article detailed how, for decades, a therapy for multiple myeloma that selects for the malignant cell and spares its benign counterpart has only been a theoretical idea. However, research from Dunn and her team at HaemaLogix has finally made this approach a reality. 

Reach more about the approach here.